乌司他丁对肝硬化肝癌患者术后免疫功能、炎症因子及肝功能的影响  

Effect of Ulinastatin on Postoperative Immune Function,Inflammatory Factors and Liver Function in Patients with Cirrhosis and Liver Cancer

作　　者：刘维良 王卫华 刘珉 LIU Weiliang;WANG Weihua;LIU Min(Qingdao Shibei District People's Hospital,Qingdao 266033,China)

机构地区：[1]青岛市市北区人民医院,山东青岛266033

出　　处：《中外医学研究》2024年第12期124-127,共4页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:对肝硬化肝癌患者术后行乌司他丁治疗并探讨对其免疫功能、炎症因子及肝功能的影响。方法:选取2021年6月—2023年6月青岛市市北区人民医院收治的98例肝硬化肝癌术后患者作为本次研究对象,按治疗方式的不同将其分为观察组(n=51)与对照组(n=47)。对照组给予常规治疗,观察组在对照组基础上给予乌司他丁治疗。比较两组免疫功能、炎症因子、肝功能及不良反应发生情况。结果:观察组治疗后CD4^(+)、CD4^(+)/CD8^(+)、免疫球蛋白G(IgG)和免疫球蛋白A(IgA)高于对照组,白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)及可溶性白细胞介素-2受体(SIL-2R)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素、总胆汁酸水平低于对照组,差异有统计学意义(P<0.05);观察组并发症发生率(5.88%)低于对照组(27.66%),差异有统计学意义(P<0.05)。结论:肝硬化肝癌患者使用乌司他丁辅助治疗可有效抑制炎症因子水平,提高免疫功能及肝功能,降低并发症发生率,且药物安全性高。Objective:To investigate the effect of Ulinastatin on immune function,inflammatory factor and liver function in patients with cirrhosis and liver cancer after operation.Method:Ninety-eight patients with cirrhosis and liver cancer after operation who admitted to Qingdao Shibei District People's Hospital from June 2021 to June 2023 were selected as the subjects of this study,and they were divided into the observation group(n=51)and the control group(n=47)according to the different treatment methods.The control group was given conventional treatment,and the observation group was given Ulinastatin on the basis of the control group.The immune function,inflammatory factors,liver function and complication were compared between two groups.Result:The CD4^(+),CD4^(+)/CD8^(+),immunoglobulin G(IgG)and immunoglobulin A(IgA)in the observation group after treatment were higher than those in the control group,while the interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),high-sensitivity C-reactive protein(hs-CRP),soluble interleukin-2 receptor(SIL-2R),alanine aminotransferase(ALT),aspartate aminotransferase(AST),total bilirubin and total bile acid levels were lower than those in the control group,and the differences were statistically significant(P<0.05);the incidence of complications in the observation group(5.88%)was lower than that in the control group(27.66%),and the difference was statistically significant(P<0.05).Conclusion:Ulinastatin adjuvant therapy in patients with cirrhosis and liver cancer can effectively inhibit the level of inflammatory factors,improve immune function and liver function,reduce the incidence of complications,and has high drug safety.

关 键 词：乌司他丁 肝硬化 肝癌 免疫功能 炎症因子 肝功能 

分 类 号：R735.7[医药卫生—肿瘤]